FDA Approved: ADBRY — Supplemental Application (LEO Pharma Inc.)

View source ↗

Summary

FDA approved a supplemental application for ADBRY (tralokinumab-ldrm) by LEO Pharma Inc., indicating a change to labeling or indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ADBRY (TRALOKINUMAB-LDRM)

Snippet

SUPPL AP for ADBRY (TRALOKINUMAB-LDRM)